Anti-Microbialvior BioteQ Co (ROCO:6864) Change In Receivables: NT$-0.22 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6864 Anti-Microbial Savior BioteQ Co Ltd ROCO:6864
65 GF Score
Price NT$48.60
GF Value NT$83.42
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Anti-Microbialvior BioteQ Co Change In Receivables?

Anti-Microbialvior BioteQ Co ROCO:6864 -1.82% 65 Change In Receivables is NT$-0.22 Mil as of Jun. 2026. GuruFocus rates ROCO:6864 with a GF Score™ of 65/100 and a GF Value™ of NT$83.42 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Anti-Microbialvior BioteQ Co's change in receivables for the quarter that ended in Jun. 2026 was NT$-0.15 Mil. It means Anti-Microbialvior BioteQ Co's Accounts Receivable increased by NT$0.15 Mil from Dec. 2025 to Jun. 2026 .

Anti-Microbialvior BioteQ Co's change in receivables for the fiscal year that ended in Dec. 2025 was NT$0.46 Mil. It means Anti-Microbialvior BioteQ Co's Accounts Receivable declined by NT$0.46 Mil from Dec. 2024 to Dec. 2025 .

Anti-Microbialvior BioteQ Co's Accounts Receivable for the quarter that ended in Jun. 2026 was NT$0.21 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Anti-Microbialvior BioteQ Co's Days Sales Outstanding for the six months ended in Jun. 2026 was 44.87.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Anti-Microbialvior BioteQ Co's liquidation value for the six months ended in Jun. 2026 was NT$347.82 Mil.

Anti-Microbialvior BioteQ Co  (ROCO:6864) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Anti-Microbialvior BioteQ Co's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.207/0.842*91
=44.87

2. In Ben Graham's calculation of liquidation value, Anti-Microbialvior BioteQ Co's accounts receivable are only considered to be worth 75% of book value:

Anti-Microbialvior BioteQ Co's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=401.111-55.487+0.75 * 0.207+0.5 * 4.089
=347.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anti-Microbialvior BioteQ Co Change In Receivables Related Terms

Anti-Microbialvior BioteQ Co Change In Receivables Historical Data

* Premium members only.

The historical data trend for Anti-Microbialvior BioteQ Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anti-Microbialvior BioteQ Co Change In Receivables Chart

Anti-Microbialvior BioteQ Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial -0.00 0.04 -0.33 -0.12 0.46

Anti-Microbialvior BioteQ Co Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 -0.18 0.53 -0.07 -0.15
ROCO:6864
65GF Score
Anti-Microbial Savior BioteQ Co Ltd ROCO:6864
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anti-Microbialvior BioteQ Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-0.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of NT$-0.22 Mil mean?
Anti-Microbialvior BioteQ Co (ROCO:6864) has a Change In Receivables of NT$-0.22 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Anti-Microbialvior BioteQ Co and its competitors.
Is Anti-Microbialvior BioteQ Co's Change In Receivables too high?
Anti-Microbialvior BioteQ Co's current Change In Receivables is NT$-0.22 Mil. Overall, Anti-Microbialvior BioteQ Co has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anti-Microbialvior BioteQ Co's Change In Receivables compare to VRTX and REGN?
Anti-Microbialvior BioteQ Co's Change In Receivables of NT$-0.22 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Anti-Microbialvior BioteQ Co and its competitors. Anti-Microbialvior BioteQ Co's current Change In Receivables is NT$-0.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anti-Microbialvior BioteQ Co stock overvalued right now?
Based on GuruFocus' analysis, Anti-Microbialvior BioteQ Co (ROCO:6864) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$83.42, compared to a current price of NT$48.60 — trading 41.7% below its estimated fair value. The current Change In Receivables is NT$-0.22 Mil. Anti-Microbialvior BioteQ Co's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Anti-Microbialvior BioteQ Co (ROCO:6864), the current Change In Receivables is NT$-0.22 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anti-Microbialvior BioteQ Co (ROCO:6864) Overvalued in 2026?

Based on GuruFocus' analysis, Anti-Microbialvior BioteQ Co stock appears to be undervalued. The current stock price of NT$48.60 is trading 41.7% below its estimated GF Value™ of NT$83.42. GuruFocus considers Anti-Microbialvior BioteQ Co to be Significantly Undervalued.

Key valuation signals for ROCO:6864:

  • Change In Receivables: NT$-0.22 Mil
  • GF Value™: NT$83.42 vs. price of NT$48.60 (41.7% below fair value)
  • GF Score™: 65/100 with 3 warning signs

No single metric tells the full story. See the ROCO:6864 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Anti-Microbialvior BioteQ Co Business Description

Address No. 6, Siwei 3rd Road, 7th Floor-2, Lingya District, Kaohsiung, TWN, 741
Anti-Microbial Savior BioteQ Co Ltd is engaged in drug research and development as well as development and technology patenting of medical fungi.
65GF Score

Get the complete analysis for ROCO:6864

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$48.60
Price
NT$83.42
GF Value